- Home
- » Tags
- » Gadoteric acid
Top View
- Incorporation of Magnetic Nanoparticles and Paramagnetic
- Fact Sheet Breastfeeding Your Baby After an MRI Or CT Scan
- Dotarem 279.32 Mg/Ml Solution for Injection in Pre-Filled Syringes
- (12) Patent Application Publication (10) Pub. No.: US 2011/0269704 A1 Seigfried (43) Pub
- Safety Evaluation of Linear and Macrocyclic Gadolinium-Based
- ACR Manual on Contrast Media (2020)
- Marrakesh Agreement Establishing the World Trade Organization
- Biem Pharmaceuticals Is
- Dotarem®) Examinations, Including 3,209 Performed on Renally Insufficient Individuals Young, Laura; Matthew, Shona; Houston, John
- )&F1y3x PHARMACEUTICAL APPENDIX to THE
- Comprehensive Contrast Policy Page 2 of 25
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- Questions & Answers Re NSF and Gadolinium, 26 June 2007
- Ml Solution for Injection Clariscan 0.5 Mmol/ Ml Solution for Injection in Pre-Filled Syringe
- Customs Tariff - Schedule Xxi - 1
- AMM Template
- Tolerability and Diagnostic Value of Gadoteric Acid in the General Population and in Patients with Risk Factors: Results in More Than 84,000 Patients
- Safety and Clinical Usefulness of Gadoteric Acid Including Post-Marketing Surveillance
- Public Assessment Report for Paediatric Studies Submitted in Accordance with Article 45 of Regulation (EC) No1901/2006, As Amended
- ARTIREM Entitled “MR Arthrography: Time-Course of an Intraarticularly Injected Gadolinium Contrast Agent” in January 2005, in Line with the Provided Protocol
- Harmonized Tariff Schedule of the United States (2006) Annotated for Statistical Reporting Purposes
- Gadolinium-Containing Agents Restrictions on Use
- The Incidence of Skin Lesions in Contrast Media- Induced Chemical Hypersensitivity
- Pharmacokinetics Uses and Administration Adverse Effects And
- Negative Oral Contrast Media for Mrcp Benefits
- Assessment Report
- (12) United States Patent (10) Patent No.: US 8,802,596 B2 Rogers Et Al
- Gbcas: Regulatory Update & Information on Guerbet's Products
- Pharmaceutical Appendix to the Tariff Schedule 2
- 204781Orig1s000
- Medicines Adverse Reactions Committee
- Effects of Gadoxetic Acid on Image Quality of Arterial Multiphase
- All India Institute of Medical Sciences Patna
- Application for Inclusion of Gadoterate Meglumine Pdf, 853Kb
- N:O 1024 3548
- Gadolinium-Containing Contrast Agents
- Absence of Potential Gadolinium Toxicity Symptoms Following 22,897
- FIXED DOSE COMBINATIONS APPROVED by DCG (I) SINCE 1961 to 28Th JUNE 2019
- Dotarem 0.5 Mmol/Ml, Solution for Injection
- Finished Products) for All Therapeutic Categories
- WO 2007/016766 Al